Family Medicine & Medical Science Research
Open Access

Genetic Mechanisms and Role of Family Genes in Cardiovascular Disease

Brandyn Mason^{* *}Correspondence: Brandyn Mason, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK, Email:

Author info »

About the Study

Cardiovascular Diseases (CVDs) represent a significant global health burden, contributing to millions of deaths each year. While lifestyle factors such as diet, exercise, smoking, and stress are commonly associated with the development of CVDs, genetic factors also play an important role in an individual’s risk for these conditions. Family genes, or hereditary factors, significantly influence cardiovascular health, with genetic predispositions shaping an individual’s likelihood of developing various heart-related conditions.

Understanding cardiovascular disease

Cardiovascular diseases encompass a wide range of disorders affecting the heart and blood vessels, including Coronary Artery Disease (CAD), hypertension, heart failure, arrhythmias, and stroke. These conditions often share common risk factors, including high blood pressure, high cholesterol, diabetes, and obesity. However, it is becoming increasingly clear that genetic factors contribute significantly to the development and progression of these diseases [1].

Genetic predisposition to CVD is not limited to a single gene or mutation. Rather, a complex interplay of multiple genes, environmental factors, and lifestyle choices shape an individual's risk profile [2].

Role of family history in cardiovascular disease

Family history is one of the most well-established risk factors for cardiovascular disease. A family history of heart disease, particularly in first-degree relatives (parents, siblings), significantly increases an individual’s risk of developing similar conditions [3].

The genetic contribution to CVD can manifest in several ways. In some cases, individuals inherit specific mutations or variations that predispose them to certain cardiovascular conditions, while in other cases, a combination of genetic risk factors may act in concert with environmental influences to increase the likelihood of developing CVD.

Genetic mechanisms involved in cardiovascular disease

The genetics of cardiovascular disease is a rapidly evolving field, with several key pathways identified as influencing the development of heart disease [4]. Some of these mechanisms include:

Inherited heart conditions: Certain inherited heart conditions, such as Familial Hypercholesterolemia (FH), Hypertrophic Cardiomyopathy (HCM), and familial Dilated Cardiomyopathy (DCM), are directly caused by genetic mutations.

Familial Hypercholesterolemia (FH): FH is a genetic disorder characterized by high cholesterol levels, particularly elevated Low-Density Lipoprotein (LDL) cholesterol, which can lead to early onset coronary artery disease. The condition is typically caused by mutations in the LDL receptor gene, resulting in impaired cholesterol clearance from the bloodstream [5].

Hypertrophic Cardiomyopathy (HCM): HCM is a genetic disorder of the heart muscle, often caused by mutations in the genes encoding proteins of the heart muscle. The condition leads to thickening of the heart walls, which can impair normal heart function and increase the risk of arrhythmias and sudden cardiac death.

Genetic variations in lipid metabolism

Genes that regulate lipid metabolism play a central role in the development of cardiovascular disease. Variations in these genes can lead to altered lipid profiles, contributing to atherosclerosis and other cardiovascular conditions [6].

Apolipoprotein E (APOE): APOE is a gene that encodes a protein involved in lipid metabolism. Certain variants of this gene, such as APOE4, are associated with an increased risk of atherosclerosis and heart disease.

PCSK9: This gene encodes a protein that regulates the number of LDL receptors on liver cells, thereby influencing blood cholesterol levels. Mutations in PCSK9 can lead to lower LDL cholesterol levels and a reduced risk of coronary artery disease, while other mutations may contribute to higher cholesterol levels and an increased risk of heart disease [7].

Blood pressure regulation genes

Hypertension, or high blood pressure, is a major risk factor for cardiovascular disease, and there is growing evidence that genetic factors play a significant role in blood pressure regulation. Variations in genes involved in sodium balance, the renin-angiotensin system, and vascular function can contribute to the development of hypertension.

Renin-Angiotensin System (RAS) genes: The renin-angiotensin system is a key regulator of blood pressure and fluid balance. Variations in genes encoding components of this system, such as the Angiotensinogen (AGT) gene, can influence blood pressure regulation and increase the risk of hypertension.

Endothelial Nitric Oxide Synthase (eNOS): The eNOS gene encodes an enzyme responsible for producing nitric oxide, a molecule that helps relax blood vessels and regulate blood flow. Variations in the eNOS gene have been linked to endothelial dysfunction and an increased risk of hypertension and cardiovascular disease [8].

Genetic testing and cardiovascular risk assessment

The field of genetic testing has made significant strides in recent years, providing valuable tools for assessing an individual’s genetic risk for cardiovascular disease. Genetic tests can identify mutations or variants associated with specific heart conditions, enabling early detection and more personalized management strategies.

Polygenic Risk Scores (PRS): One promising approach in genetic risk assessment is the use of polygenic risk scores. These scores aggregate the effects of multiple genetic variants, each contributing a small amount to an individual’s overall risk for cardiovascular disease [9].

Genetic screening for specific heart conditions: Genetic testing can also be used to identify individuals at risk for inherited heart conditions, such as familial hypercholesterolemia or hypertrophic cardiomyopathy. Early identification of these conditions allows for more effective management, including lifestyle changes, medications, or even surgical interventions to reduce the risk of adverse cardiovascular events [10].

Family medicine plays a pivotal role in managing cardiovascular disease, particularly in individuals with a significant family history of these conditions. By offering comprehensive and continuous care, family physicians can monitor genetic risk factors and their interaction with lifestyle and environmental influences over time. They provide personalized health education, promote preventive measures such as regular screenings and genetic counseling, and manage modifiable risk factors like hypertension, diabetes, and high cholesterol. Through a holistic approach, family medicine bridges the gap between genetic predisposition and proactive cardiovascular care, potential better outcomes for patients at risk.

References

1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478-3490.

   [Crossref] [Google Scholar] [PubMed]

2. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484-493.

   [Crossref] [Google Scholar] [PubMed]

3. Brown MS, Goldstein JL. Lowering LDL--not only how low, but how long?. Science. 2006;311(5768):1721-173.

   [Crossref] [Google Scholar] [PubMed]

4. Goldstein JL, Brown MS. Familial hypercholesterolemia: Pathogenesis of a receptor disease. Johns Hopkins Med J. 1978;143(1):8-16.

   [Google Scholar] [PubMed]

5. Morganroth J, Levy RI, McMahon AE, Gotto Jr AM. Pseudohomozygous type II hyperlipoproteinemia. J Pediatr. 1974;85(5):639-643.

   [Crossref] [Google Scholar] [PubMed]

6. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: Low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 1987;84(19):6919-6923.

   [Crossref] [Google Scholar] [PubMed]

7. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.

   [Crossref] [Google Scholar] [PubMed]

8. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.

   [Crossref] [Google Scholar] [PubMed]

9. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): A double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529.

   [Crossref] [Google Scholar] [PubMed]

10. Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: A non-inferiority randomized controlled trial. Nat Med. 2022;28(1):89-95.

    [Crossref] [Google Scholar] [PubMed]